Kamlanoflast for amyotrophic lateral sclerosis
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called kamlanoflast to see if it can slow the progression of ALS. It is for people with a recent diagnosis who are showing signs of active disease, and it may help reduce nerve damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a definite or probable diagnosis of ALS (based on standard research criteria).
- You are between 18 and 75 years old.
- Your first symptoms of weakness started within the past 3 years.
- Your ALS is progressing at a certain rate (about half a point per month on a standard ALS functional scale).
- A blood test shows a high level of a nerve damage marker called neurofilament light (NfL).
- You can swallow pills and liquids, or use a feeding tube, and you have good breathing function (measured by a breathing test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new nasal spray medicine called foralumab to see if it is safe and can slow down ALS. The trial is part of the Healey ALS platform and uses special scans to check how the medicine affects the brain.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This trial tests a new medicine called LY4256984 for people with sporadic ALS (ALS not caused by a known genetic mutation). The goal is to see if the drug is safe and how it affects the body. It may offer a new treatment option for people recently diagnosed with ALS.
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.
Hear when a new Neuro-Degenerative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.